Depressão resistente: o que é, causas, sintomas e como tratar
A escetamina é um novo fármaco, que tem sido amplamente investigado e utilizado como uma opção de tratamento inovadora para a depressão ...
dados
A depressão resistente é mais comum do que se possa pensar. Os <anchor>dados</anchor> indicam que cerca de 15% das pessoas têm depressão, em algum momento das suas vidas. Destes doentes, 20% não responde bem ao tratamento, mas isso não significa que não há nada a fazer. Descubra o que é a depressão resistente e quais os tratamentos inovadores que já estão disponíveis.
Real-world evidence from a European cohort study of patients with treatment resistant depression: Treatment patterns and clinical outcomes - ScienceDirect
- View PDF
- Download full issue

Search ScienceDirect

## Journal of Affective Disorders

# Research paper  Real-world evidence from a European cohort study of patients with treatment resistant depression: Treatment patterns and clinical outcomes

Author links open overlay panelK.Heerleina, G.Perugib, C.Ottec, T.Frodld, G.Degraeveef, W.Hagedoorng, A.J.Oliveira-Maiahi, V.Perez Solaj, S.Rathodk, G.Rossol, P.Sierram, S.Malynnn, J.Morrenso, C.Verrijckenp, B.Gonzalezq, A.H.Youngrs

Show more

Add to Mendeley

Share

Cite

Under a Creative Commons license

open access

## Highlights

- •
  Real-world data on treatment resistant depression (TRD) in Europe are lacking

- •
  No treatment consensus has been reached; in this study, treatments varied widely

- •
  After 6 months of routine clinical care, 73.5% of patients had not responded

- •
  At Month (M) 6, 16.7% of patients were in remission but 33.3% lost remission by M12

- •
  Despite low remission rates, 60.0% of patients had not changed treatment at M12

## Abstract

### Background

Treatment resistant depression (TRD) characterizes a subgroup of 10–30% of patients with major depressive disorder, and is associated with considerable morbidity and mortality. A consensus treatment for TRD does not exist, which often leads to wide variations in treatment strategies. Real-world studies on treatment patterns and outcomes in TRD patients in Europe are lacking and could help elucidate current treatment strategies and their efficacy.

### Methods

This non-interventional cohort study of patients with TRD (defined as treatment failure on ≥2 oral antidepressants given at adequate dose and duration) with moderate to severe depression collected real-world data on treatment patterns and outcomes in several European countries. Patients were started on a new treatment for depression according to routine clinical practice.

### Results

Among 411 patients enrolled, after 6 months, only 16.7% achieved remission and 73.5% showed no response. At Month 12, while 19.2% achieved remission and 69.2% showed no response, 33.3% of those in remission at Month 6 were no longer in remission. Pharmacological treatments employed were heterogenous; 54 different drugs were recorded at baseline, and the top 5 treatment types according to drug classes accounted for 40.0% of patients. Even though remission rates were very low, at Month 12, 60.0% of patients had not changed treatment since enrolment.

### Conclusions

The heterogeneity of treatments highlights a lack of consensus. Moreover, despite low response rates, patients often remained on treatments for substantial periods of time. These data further support existence of an unmet treatment need for TRD patients in Europe.

- Previousarticle in issue
- Nextarticle in issue

Recommended articles

## Cited by (0)

© 2021 The Author(s). Published by Elsevier B.V.

## Recommended articles

No articles found.

## Article Metrics

Cookies are used by this site. Cookie Settings

All content on this site: Copyright © 2024 Elsevier B.V., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the Creative Commons licensing terms apply.